Literature DB >> 10836692

Use of fusion images of I-131 metaiodobenzylguanidine, SPECT, and magnetic resonance studies to identify a malignant pheochromocytoma.

A Fujita1, H Hyodoh, Y Kawamura, K Kanegae, M Furuse, K Kanazawa.   

Abstract

Pheochromocytoma is a chromaffin tumor in which 10% are extra-adrenal and 10% are malignant. I-131 metaiodobenzylguanidine (MIBG) scintigraphy has an important role in the identification of these tumors and investigation of metastatic lesions. The authors describe a 36-year-old woman who underwent resection of a malignant left adrenal pheochromocytoma who was thought to have metastases in the liver and para-aortic lymph nodes. Fusion images of I-131 MIBG SPECT and magnetic resonance studies were obtained to properly identify the metastatic lesions. These fusion images helped greatly in subsequent surgery.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10836692     DOI: 10.1097/00003072-200006000-00010

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

Review 1.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

Review 2.  Extra-adrenal pheochromocytoma: diagnosis and management.

Authors:  Grant I S Disick; Michael A Palese
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

3.  Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.

Authors:  Ioannis Ilias; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Ivica Lazúrová; Karen T Adams; Shiromi Perera; Karel Pacak
Journal:  J Nucl Med       Date:  2008-09-15       Impact factor: 10.057

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.